Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

• H.C. Wainwright 3^rd Annual BioConnect Investor Conference (New York, NY)
  Tuesday, May 20, 2025
  Fireside Chat at 10:00 a.m. Eastern Time

• Jefferies Global Healthcare Conference (New York, NY)
  Wednesday, June 4, 2025
  Fireside Chat at 9:55 a.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
[email protected]

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]

Media Contact:
Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
[email protected]

This press release was published by a CLEAR® Verified individual.